Catastrophic antiphospholipid antibody syndrome provoked by eltrombopag
- 22 March 2025
- journal article
- Published by BMJ in Practical Neurology
- Vol. 25 (5) , 448-451
Abstract
Antiphospholipid antibody syndrome (APS) may rarely present with isolated thrombocytopenia that may be diagnosed and treated as immune thrombocytopenic purpura. A 32-year-old woman was given eltrombopag (a thrombopoietin receptor agonist) to treat presumed immune thrombocytopenic purpura. She developed catastrophic APS, with multiple ischaemic infarcts, microvascular coronary thrombosis and digital gangrene. She improved after stopping eltrombopag and starting immunotherapy (corticosteroids, intravenous immunoglobulin and rituximab) but was left with significant neurological morbidity.Keywords
This publication has 10 references indexed in Scilit:
- Platelets and Thrombotic Antiphospholipid SyndromeJournal of Clinical Medicine, 2024
- Hematological Activity in Primary Antiphospholipid Syndrome: A Common Manifestation Outside the Classification CriteriaBlood, 2023
- Catastrophic antiphospholipid syndrome in an immune thrombocytopenia patient treated with avatrombopagResearch and Practice in Thrombosis and Haemostasis, 2023
- Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature reviewMedicine, 2023
- Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonistsRheumatology, 2018
- Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonistSeminars in Arthritis and Rheumatism, 2016
- Thrombopoietin Receptor Agonists in Primary Immune ThrombocytopeniaSeminars in Hematology, 2013
- Lessons from the catastrophic antiphospholipid syndrome (CAPS) registryAutoimmunity Reviews, 2006
- Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1Arthritis & Rheumatism, 1998
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981